Carregant...
Long lasting response to second-line everolimus in kidney cancer
In the case presented here, everolimus was administered after first line therapy with sunitinib in a patient with metastatic renal cell carcinoma. The safety profile was excellent. The prolonged progression-free survival (PFS) obtained with everolimus in this case is of peculiar interest, as it is a...
Guardat en:
| Autors principals: | , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Baishideng Publishing Group Co., Limited
2013
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3845942/ https://ncbi.nlm.nih.gov/pubmed/24303493 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.12998/wjcc.v1.i5.166 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|